These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22771885)

  • 41. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma.
    Park KJ; Kim HS; Park JE; Shim WH; Kim SJ; Smith SA
    Eur Radiol; 2016 Dec; 26(12):4390-4403. PubMed ID: 26883333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
    Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
    Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
    Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
    Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glioblastoma multiforme versus solitary supratentorial brain metastasis: differentiation based on morphology and magnetic resonance signal characteristics.
    Maurer MH; Synowitz M; Badakshi H; Lohkamp LN; Wüstefeld J; Schäfer ML; Wiener E
    Rofo; 2013 Mar; 185(3):235-40. PubMed ID: 23196836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.
    Kuhl CK; Schild HH; Morakkabati N
    Radiology; 2005 Sep; 236(3):789-800. PubMed ID: 16118161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging.
    Parikh T; Drew SJ; Lee VS; Wong S; Hecht EM; Babb JS; Taouli B
    Radiology; 2008 Mar; 246(3):812-22. PubMed ID: 18223123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI.
    Chen X; Wei X; Zhang Z; Yang R; Zhu Y; Jiang X
    Clin Imaging; 2015; 39(5):775-80. PubMed ID: 25956436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
    Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
    J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
    Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
    Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
    Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns.
    Park MJ; Kim YK; Lee MW; Lee WJ; Kim YS; Kim SH; Choi D; Rhim H
    Radiology; 2012 Sep; 264(3):761-70. PubMed ID: 22843769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma.
    Akgoz A; Rahman R; You H; Qu J; Hamdan A; Seethamraju RT; Wen PY; Young GS
    J Neurooncol; 2014 Aug; 119(1):111-9. PubMed ID: 24792644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
    Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
    Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamic susceptibility contrast MRI in advanced pancreatic cancer: semi-automated analysis to predict response to chemotherapy.
    Niwa T; Ueno M; Shinya N; Gotoh T; Kwee TC; Takahara T; Yoshida T; Ohkawa S; Doiuchi T; Inoue T
    NMR Biomed; 2010 May; 23(4):347-52. PubMed ID: 19950116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients.
    Kim TH; Yun TJ; Park CK; Kim TM; Kim JH; Sohn CH; Won JK; Park SH; Kim IH; Choi SH
    Oncotarget; 2017 Mar; 8(12):20340-20353. PubMed ID: 27823971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions.
    Lee EJ; terBrugge K; Mikulis D; Choi DS; Bae JM; Lee SK; Moon SY
    AJR Am J Roentgenol; 2011 Jan; 196(1):71-6. PubMed ID: 21178049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.